Ustekinumab treatment is associated with decreased systemic and vascular inflammation in patients with moderate to severe psoriasis: Feasibility study using 18F-fluorodeoxyglucose positron emission tomography-computed tomography
Psoriasis may be associated with metabolic syndrome and an increased risk of cardiovascular disease.; Patients with psoriasis had increased hepatic, splenic, and arterial inflammation, which decreased with ustekinumab therapy.; Ustekinumab treatment was significantly associated with decreased systemic and vascular inflammation related to metabolic syndrome and cardiovascular disease among patients with psoriasis.
Source: Journal of the American Academy of Dermatology - Category: Dermatology Authors: Byung-Soo Kim, Won-Ku Lee, Kyoungjune Pak, Junhee Han, Gun-Wook Kim, Hoon-Soo Kim, Hyun-Chang Ko, Moon-Bum Kim, Seong-Jang Kim Source Type: research
More News: Academies | Cardiology | Cardiovascular | CT Scan | Dermatology | Heart | Metabolic Syndrome | PET Scan | Psoriasis | Skin | Stelara | Study